RE:RE:RE:RE:RE:RE:Other regional deals could follow quicklyIf the FDA drags its feet while RVX confirms its product works in trials outside the US, as in the Phase III European trial, we will still know the technology works. That's the main risk and source of value - does the technology work. It will only be a matter of time before clearing a Phase III trial in the US if we know it works. With interest rates as low as they are the market doesn't care much about having to wait a couple more years for US approval, as long as they know the product works. With low interest rates a dollar today is only worth 1% more next year. Waiting isn't that costly; again, as long as we know the product works.